Most Read Articles
6 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

4 days ago
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
6 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
Yesterday
Cabozantinib is not better than mitoxantrone-prednisone at relieving pain in patients with metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastasis, a recent study suggests.

Protection against invasive meningococcal disease: Current trends

05 Dec 2017
At a continuing medical education webcast hosted by GlaxoSmithKline, Dr Bruce Mungall discussed preventive strategies against invasive meningococcal disease (IMD). Highlights of his presentation are summarized here.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

4 days ago
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
6 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
Yesterday
Cabozantinib is not better than mitoxantrone-prednisone at relieving pain in patients with metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastasis, a recent study suggests.